Slide 1: Second Quarter 2021 Operating & Financial Results Conference Call
Second Quarter 2021 Operating & Financial Results Conference Call July 29, 2021 https://ir.lanternpharma.com/ 4:30 PM Eastern
Slide 2: Forward-Looking Statements
LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 3: Key Topics
KEY TOPICS 1. Business Overview & Background Panna Sharma, CEO 2. Financial Results & Highlights David Margrave, CFO Second Quarter 2021 3. Business Updates Operating & Financial Panna Sharma, CEO Results Conference Call 4. Milestones Panna Sharma, CEO 5. Q&A Session July 29, 2021 4:30 PM Eastern Pa
Slide 4: Lantern leverages A.I. to rescue and develop cancer therapies
Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development Failed or Abandoned Responders Non-Responders Drug Assets & New Drug RADR® Development • Patient stratification based on A.I. enabled • Big data (genomic,
Slide 5: Lantern's Unique & Rapidly Developing Pipeline
Lantern’s Unique & Rapidly Developing Pipeline Indication Program R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 (Metastatic Castration-Resistant Prostate Cancer) (Irofulven) Non-Small Cell Lung Cancer LP-300 Targeting sub-population in (Focused on Never-Smokers) NSCLC of Adenocar
Slide 6: Highlights & Key Milestones Attained During 2Q'21
Highlights & Key Milestones Attained During 2Q’21 • Announced positive preclinical data in pancreatic cancer from in-vivo animal models where tumor shrinkage was observed as being an average of 93% over 8 weeks • Initiated development of LP-184 in DNA damage repair deficient tumors, including bladde
Slide 7: Summary Results of Operations
Summary Results of Operations Three Months Ended Six Months Ended June 30, June 30, (Unaudited) (Unaudited) 2021 2020 2021 2020 Operating expenses: General and administrative 1,314,201 676,399 2,487,459 1,016,571 Research and development 1,164,892 157,023 2,443,929 294,127 Total operating expenses 2
Slide 8: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary 6/30/2021 12/31/2020 Cash and Marketable Securities $ 79,588,657 $ 19,229,232 Prepaid Expenses & Other Current Assets $ 2,542,426 $ 1,007,690 Total Assets $ 82,432,073 $ 20,359,634 Total Liabilities $ 2,818,809 $ 660,839 Total Stockholders’ Equity $ 79,613,264 $ 19
Slide 9: Shares Outstanding
Shares Outstanding June 30, 2021 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 11,184,039 Warrants 302,036 Options (Employees, Management and Directors) 823,826 Fully Diluted Shares Outstanding 12,309,901 9
Slide 10: Entering "The Golden Age of A.I. in Medicine"
Entering “The Golden Age of A.I. in Medicine” 10 Mega-Trends Setting The Stage for A.I. Led Transformation in Drug Development & Medicine ✦ Large-scale, relevant and readily available data-sets ✦ Methods, technologies and algorithms that are massively scalable ✦ Computing, storage and transmission c
Slide 11: The RADR Platform Enables...
The RADR® Platform Enables... ➢ Rapid identification of potential compounds to Data Points Powering RADR® rescue and develop Scientific Value + ➢ Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks ➢ Feedback for potential mechanisms to
Slide 12: RADR Platform Key Features & Architecture
RADR® Platform Key Features & Architecture 80%+ RADR® rapidly identifies genetic & Prediction 1 biomarker signatures for Success precision oncology drug ~27,000+ development, clinical response Patient Records prediction and CDx (companion diagnostic) enablement. 144+ Drug-Tumor Interactions: Over 90
Slide 13: Growth in Data Drives Growth in Capabilities: 16.7x Growth
Growth in Data Drives Growth in Capabilities: 16.7x Growth Over Last 12 Months (July 2020 to July 2021) • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number & mutation data • Clinical stage of tumor/cancer • Histology of tumor • Patient age and sex • Pat
Slide 14: Reacquired Rights to LP-100 (Irofulven) & Phase 2 Clinical Trial
Reacquired Rights to LP-100 (Irofulven) & Phase 2 Clinical Trial in Metastatic Prostate Cancer + Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S ▪ LP-100, Irofulven, is in an existing phase 2 clinical trial for patients with mCRPC (metastatic, castration-r
Slide 15: Positive Preclinical Data in Pancreatic Cancer with LP-184
Positive Preclinical Data in Pancreatic Cancer with drug candidate LP-184 LP-184 is a next generation DNA-damaging agent for pancreatic cancer in a research collaboration with Fox Chase Cancer Center Tumor growth inhibition of 109% was observed with LP-184 treatment relative to control. Preclinical
Slide 16: Expanding LP-184 in additional genomically-targeted indications
Expanding LP-184 in additional genomically-targeted indications – Large scale data mining suggests occurrence of NER pathway mutations in a significant proportion of Bladder Cancers Urothelial bladder cancers & NER pathway mutations Estimated Annual Cases ~ 40% 573,278- Global 83,730 - USA @40% = 33
Slide 17: Key Value Building Objectives
Key Value Building Objectives Foundational Year Multiple Streams of Value Creation Advance Platform Launch Multiple Precision Trials Prepare Trial Launches Leverage Platform for Pharma Partners Prioritize Additional Compounds Secure Additional Compounds 2021 2022 ● LP-300 - Initiate clinical trial s
Slide 18: Q&A
Q&A LTRN Operating & Financial Results Call July 29, 2021 18